Effect of 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride (Voluven®) on complications after subarachnoid hemorrhage: a retrospective analysis
| Autor: | Gavin W. Britz, Michael L. James, Sankalp Gokhale, Ulysses T. Null, Tong J. Gan, Owoicho Adogwa, Ali R. Zomorodi, Shariq Ali Khan, Terence Verla, David L. McDonagh, William D. White |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
medicine.medical_specialty
Resuscitation Subarachnoid hemorrhage Hydroxyethyl starch Sodium chemistry.chemical_element Fluid therapy medicine Retrospective analysis In patient cardiovascular diseases Major complication Mortality Delayed cerebral ischemia reproductive and urinary physiology Multidisciplinary business.industry Research 6% HES 130/0.4 Voluven Rebleeding medicine.disease nervous system diseases Surgery Hydrocephalus chemistry biological phenomena cell phenomena and immunity business medicine.drug |
| Zdroj: | SpringerPlus |
| ISSN: | 2193-1801 |
| DOI: | 10.1186/2193-1801-2-314 |
| Popis: | Background 6% Hydroxyethyl Starch 130/0.4 in 0.9% Sodium Chloride (Voluven®; 6% HES 130/0.4) is a colloid often used for fluid resuscitation in patients with subarachnoid hemorrhage (SAH), despite a lack of safety data for this use. The purpose of our study was to evaluate the effect of 6% HES 130/0.4 on major complications associated with SAH. Methods Medical records of all patients presenting between May 2010 and September 2012 with aneurysmal SAH were analyzed. Patients were divided in two groups based on the administration of 6% HES 130/0.4; HES group (n=57) and Non-HES group (n=72). The primary outcome included a composite of three major complications associated with SAH: Delayed Cerebral Ischemia (DCI), Hydrocephalus (HCP) requiring cerebrospinal fluid (CSF) shunting, and Rebleeding. Results The study groups were similar with respect to most characteristics except the incidences of hypertension, ischemic heart disease, Fisher grade and lowest hemoglobin during stay. The odds of developing the primary composite outcome was higher in the HES group [OR= 3.1(1.30-7.36), p=0.01]. The patients in the HES group had a significantly longer median duration of hospital (19 vs 14 days) and Neurointensive Care Unit stay (14 vs 10 days) compared to the Non HES group. Conclusion We observed increased complications after SAH with 6% HES 130/0.4 (Voluven®) administration. An adequately powered prospective randomized controlled trial into the safety of 6% HES 130/0.4 in this patient population is warranted. Electronic supplementary material The online version of this article (doi:10.1186/2193-1801-2-314) contains supplementary material, which is available to authorized users. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink